Home > Insider Trading > Filing (0001209191-14-070288)

Filing Details

Accession Number:: 0001209191-14-070288
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2014-11-20 13:11:24
Reporting Period:: 2014-11-13

Filing Date:: 2014-11-20
Accepted Time:: 2014-11-20 13:11:24
Original Submission Date:: 2014-11-17
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1492426	Horizon Pharma Plc	HZNP	Pharmaceutical Preparations (2834)	272179987

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1619077	Virinder Nohria	111 Skyline View Road Franklin NC 28734		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares, Nominal Value $0.0001 Per Share	Disposition	2014-11-13	2,000,000	$11.54	214,836	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Footnotes

This Form 4/A amends that certain Form 4 filed by the Reporting Person on November 17, 2014. On November 13, 2014, Dr. Nohria agreed to sell 1,739,130 ordinary shares pursuant to that certain Underwriting Agreement, dated as of November 13, 2014 (the "Underwriting Agreement"), among the Issuer, the several selling shareholders (the "Selling Shareholders") named in Schedule I to the Underwriting Agreement and Morgan Stanley & Co. LLC, Citigroup Global Markets Inc., Cowen and Company, LLC and Jefferies LLC, as representatives of the several underwriters (the "Underwriters") named in Schedule II to the Underwriting Agreement. Dr. Nohria also granted the Underwriters the option to purchase an additional 260,870 ordinary shares. On November 18, 2014, the Underwriters exercised their option to purchase the additional ordinary shares. The numbers in the table above have been amended to relect the exercise by the Underwriters of their option to purchase additional shares.
(continued from footnote 1) The price to the public was $12.05 per ordinary share and the proceeds to Dr. Nohria was $11.537875 per ordinary share. In addition, in connection with the sale of ordinary shares, the Issuer also paid an aggregate of $2,564,766 to Altiva Capital, LLC, Dr. Nohria and Mohun Patrick Nohria 2013 Gift Trust (the "Reimbursed Shareholders") in connection with the sale of the ordinary shares by such Reimbursed Shareholders pursuant to the Underwriting Agreement, each Reimbursed Shareholder to receive its pro rata amount based on the number of shares to be sold by such Reimbursed Shareholder (or $0.262125 per share).